Shailendra Singh (Shelly) is Chief Operating Officer of MnM and a member of its board. He focuses on global sales and client services functions, as well as commercial optimization at MarketsandMarkets. He has years of expe¬rience in global delivery and outsourcing sector in the IT/ Consulting/Analytics/Big Data sectors. Prior to MnM, he was leading the global sales, client services and commercial ef¬fectiveness functions for Mu Sigma, a unicorn company and a leading global provider of Decision Sciences and Big Data analytics solutions.
Roy Baynes is Senior Vice President Global Clinical Development and Chief Medical Officer at Merck Research Laboratories in Rahway, New Jersey. He was previously Senior Vice President of Oncology, Inflammation and Respiratory Therapeutics at Gilead Sciences and prior to that was Vice President Global Clinical Development and Therapeutic Area (TA) Head for Hematology / Oncology, at Amgen Inc. In the early years of his tenure at Amgen before becoming TA head of Hematology / Oncology in Clinical Development he was TA head for Hematology / Oncology in Global Medical Affairs. He graduated as a Medical Doctor and obtained a Master of Medicine and Doctor of Philosophy from the University of the Witwatersrand, Johannesburg, South Africa. He has had a long and distinguished career in the haematology-oncology-and stem cell transplantation fields, including drug development, basic research, clinical practice, clinical research, teaching and administration. He is a member of many international societies, including the American Society of Hematology (ASH) and the American Society of Clinical Oncology (ASCO), and has authored some 150 publications. He has been recurrently named among America’s top physicians. Before joining Amgen in 2002, he was the Charles Martin Professor of Cancer Research at the Barbara Ann Karmanos Cancer Institute, an NCI designated Comprehensive Cancer Center, at Wayne State University, Detroit, Michigan, USA.
John joined Kite in February 2015 and is currently a Senior Director in the Department of Translational Medicine. John leads the Cell Therapy Clinical Pharmacology group and also supports or leads biomarker activities related to clinical development of Kite’s CAR T-cell pipeline. At Kite, John has led the development of a biomarker strategy and has also built an effective translational team to support the clinical development of axicabtagene ciloleucel/KTE-C19 and KTE-X19. During this time, John’s team has contributed directly to the US and European approval of axicabtagene ciloleucel through pharmacokinetic and pharmacodynamic evaluation of this product. Among many achievements at Kite, John has represented Kite through external scientific presentations and collaborative manuscripts with leading academic researchers such as Dr. Steven Rosenberg and Dr. James Kochenderfer at the National Cancer Institute. Scientific accomplishments include the discovery of novel metrics to characterize CAR T cells based on their functionality, novel biomarker knowledge of how CAR T cells work in the clinic, mechanistic information on CAR-related toxicities, novel insights into the biology of the tumor immune microenvironment, including immune checkpoints, and the pivotal role of IL-15 in the context of CAR T-cell function.
Dr. Williams is the President and CEO of BriaCell Corporation, where he has shepherded Bria-IMT™ into the clinic, established positive proof-of-concept, forged a collaboration with Incyte for novel combinations and coordinated the development of an off-the-shelf personalized approach to cancer immunotherapy. While at Incyte Corporation as Head of Exploratory Development, he brought numerous molecules into the clinic and established proof of concept in several disease areas. At GlaxoSmithKline he worked to bring several molecules into the clinic, ran a biomarker laboratory and spearheaded initiatives to utilize emerging technologies in drug development. At the University of Pennsylvania, he developed novel methods of bioactive peptide design, ran a major research program in receptor biology, and was able to bring novel therapies into the clinic. He has been involved in several successful new drug applications, including drugs for lymphoma, ovarian cancer, osteoporosis, nausea and vomiting, myelofibrosis and polycythemia vera.
Dr. Balveen Kaur is Professor and John P. and Kathrine G. McGovern Distinguished Chair within the department of Neurological surgery. She has an active research interest in translational therapeutics and is considered an expert in the field of oncolytic viral therapy. Dr. Kaur has published more than 100 manuscripts and book chapters pertaining to cancer biology, tumor microenvironment and novel therapeutics. She has a strong track record of mentoring students and post-doctoral fellows. She also serves on several national/international committees, and has been an invited chair on several NIH study sections and review panels. She is Principal Investigator/Project leader on several NIH grants pertaining to Neuro-oncology.
Scott K. Durum PhD trained at Oak Ridge, National Jewish Denver and Yale before coming to the National Cancer Institute, National Institutes of Health where he is chief of the Section of Cytokines and Immunity. His lab has studied the role of cytokines in the immune system, with a long interest in the IL-7 pathway which is essential for T lymphocyte development and survival. His lab together with collaborators found gain-of-function mutations in the IL-7 receptor that drive acute lymphoblastic leukemia, the most common cancer in children. They are currently studying the mechanism of leukemogenesis and developing therapeutics to target the pathway. He also plays in NIH’s band, the Affordable Rock n Roll Act.
Dr. Lokesh Agrawal at NCI, directs and leads projects on biospecimen integrity and understanding the role of biospecimens in biomarker development by studying pre-analytical variables using molecular approaches. Currently at NCI he also leads and directs a Cancer Moonshot Biobanking program. Dr. Agrawal has expertise in biomarker development including clinical laboratory science and regulatory experience to strengthen programs in biospecimen acquisition and biospecimen research. Before joining NCI in 2012, Dr. Agrawal worked at MedImmune Inc./ Astrazeneca, and Rapid pharmaceuticals where he was a team leader on various projects involving pre-clinical/clinical biomarker assay development/validation and managed several cross functional teams across to qualify and validate clinical biomarker assays in oncology, vaccine and infectious diseases space. Dr. Agrawal also led and directed several gene therapy NIH-sponsored projects at Thomas Jefferson University and did his postdoctoral fellowship at Indiana University-Purdue University at Indianapolis (IUPUI, where he discovered the role of CCR5 Delta32 protein in HIV pathogenesis. He earned his Ph.D. from All India Institute of Medical Sciences, India and has authored and co-authored several manuscripts in high impact journals. Dr. Agrawal current main interests include development and validation of predictive and prognostic biomarkers using biospecimen science for cancer treatment and diagnosis.
Tullia C. Bruno, PhD, is an Assistant Professor in the Department of Immunology at the University of Pittsburgh and a faculty member in the Tumor Microenvironment Center and the Cancer Immunology and Immunotherapy Program at the UPMC Hillman Cancer Center. She obtained her Ph.D. in Immunology from Johns Hopkins in 2010 and completed her postdoctoral fellowship at the University of Colorado in 2015—both with a focus in tumor immunology. While Dr. Bruno’s PhD training focused on inhibitory receptors on intratumoral T cells, she became interested in tumor infiltrating B cells during her postdoctoral fellowship and has built her independent research program around understanding their function in multiple human cancers, in particular, lung and head and neck cancer. Dr. Bruno’s overall research objective is to develop a B cell-specific immunotherapy in the next five to ten years.
Dr. Shahram Salek-Ardakani is a Senior Director in Cancer Immunology Discovery Unit at Pfizer. His Research focuses predominantly on mechanisms of T cell memory, dendritic cell activation, and immune regulation by members of the TNF/TNFR superfamily. His group uses a variety of molecular, cellular, and biochemical techniques, as well as live cell imaging approaches to further understand biological pathways related to cancer immunotherapy. His current roles include liaisons across Early Discovery Research, Clinical and Translational Oncology and Business Development. Dr. Salek-Ardakani completed his PhD at the Patterson Institute for Cancer Research, University of Manchester, U.K, and his postdoctoral training at the La Jolla Institute for Allergy and Immunology in San Diego, CA. Dr. Salek-Ardakani has served on a number of grant review study sections and special emphasis panels for the National Institute of Health and has served on the advisory boards of professional conferences and a faculty of many seminars.